Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Metformin is used as a first-line oral treatment for type 2 diabetes (T2D). However, the underlying mechanism is not fully understood. Here, we aimed to comprehensively investigate the pleiotropic effects of metformin. RESEARCH DESIGN AND METHODS: We analyzed both metabolomic and genomic data of the population-based KORA cohort. To evaluate the effect of metformin treatment on metabolite concentrations, we quantified 131 metabolites in fasting serum samples and used multivariable linear regression models in three independent cross-sectional studies (n = 151 patients with T2D treated with metformin [mt-T2D]). Additionally, we used linear mixed-effect models to study the longitudinal KORA samples (n = 912) and performed mediation analyses to investigate the effects of metformin intake on blood lipid profiles. We combined genotyping data with the identified metformin-associated metabolites in KORA individuals (n = 1,809) and explored the underlying pathways. RESULTS: We found significantly lower (P < 5.0E-06) concentrations of three metabolites (acyl-alkyl phosphatidylcholines [PCs]) when comparing mt-T2D with four control groups who were not using glucose-lowering oral medication. These findings were controlled for conventional risk factors of T2D and replicated in two independent studies. Furthermore, we observed that the levels of these metabolites decreased significantly in patients after they started metformin treatment during 7 years’ follow-up. The reduction of these metabolites was also associated with a lowered blood level of LDL cholesterol (LDL-C). Variations of these three metabolites were significantly associated with 17 genes (including FADS1 and FADS2) and controlled by AMPK, a metformin target. CONCLUSIONS: Our results indicate that metformin intake activates AMPK and consequently suppresses FADS, which leads to reduced levels of the three acyl-alkyl PCs and LDL-C. Our findings suggest potential beneficial effects of metformin in the prevention of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
Bauer, D. J., Preacher, K. J., & Gil, K. M. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.142 · Cited by 1,704
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Human metabolic individuality in biomedical and pharmaceutical research
CARDIoGRAM, Suhre, K., Shin, S.-Y., Petersen, A.-K., Mohney, R. P., Meredith, D., Wägele, B., Altmaier, E., Deloukas, P., Erdmann, J., et al. (2011) · Nature · doi:10.1038/nature10354 · Cited by 1,017
Self-citationFloegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.-G., Fritsche, A., Häring, H.-U., Hrabě de Angelis, M., Peters, A., et al. (2013) · Diabetes · doi:10.2337/db12-0495 · Cited by 988
Self-citationGenetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum
Gieger, C., Geistlinger, L., Altmaier, E., Hrabé de Angelis, M., Kronenberg, F., Meitinger, T., Mewes, H.-W., Wichmann, H.-E., Weinberger, K. M., Adamski, J., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000282 · Cited by 737
Self-citationNovel biomarkers for pre-diabetes identified by metabolomics
Wang‐Sattler, R., Yu, Z., Herder, C., Messias, A. C., Floegel, A., He, Y., Heim, K., Campillos, M., Holzapfel, C., Thorand, B., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.43 · Cited by 701
Self-citationHuman serum metabolic profiles are age dependent
Yu, Z., Zhai, G., Singmann, P., He, Y., Xu, T., Prehn, C., Römisch‐Margl, W., Lattka, E., Gieger, C., Soranzo, N., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00865.x · Cited by 340
Self-citation
Cited by
AMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 754
Metformin: a review of its potential indications
Wang, Y.-W., He, S.-J., Feng, X., Cheng, J., Luo, Y.-T., Tian, L., & Huang, Q. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s141675 · Cited by 320
NF‐κB as the mediator of metformin's effect on ageing and ageing‐related diseases
Kanigur Sultuybek, G., Soydas, T., & Yenmis, G. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13073 · Cited by 119
Adam, J., Brandmaier, S., Leonhardt, J., Scheerer, M. F., Mohney, R. P., Xu, T., Bi, J., Rotter, M., Troll, M., Chi, S., et al. (2016) · Diabetes · doi:10.2337/db16-0512 · Cited by 68
“Our previous study was based on a targeted metabolomics approach to explore the effects of metformin on lipid profiles in the population-based KORA (Cooperative Health Research in the Region of Augsburg) cohort (6,13,14).”
BackgroundMethodSelf-citationNew Insights Into the Anti-Diabetic Actions of Metformin: From the Liver to the Gut
Wu, T., Horowitz, M., & Rayner, C. K. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1273769 · Cited by 64
“The resulting increase in fecal bile acid excretion enhances bile acid synthesis from cholesterol, which is likely to account for metformin-induced lowering of serum cholesterol concentrations [56,57].”
Background
Metadata
- Authors
- Xu, T., Brandmaier, S., Messias, A. C., Herder, C., Draisma, H. H. M., Demirkan, A., Yu, Z., Ried, J. S., Haller, T., Heier, M., Campillos, M., Fobo, G., Stark, R., Holzapfel, C., Adam, J., Chi, S., Rotter, M., Panni, T., Quante, A. S., He, Y., Prehn, C., Roemisch-Margl, W., Kastenmüller, G., Willemsen, G., Pool, R., Kasa, K., van Dijk, K. W., Hankemeier, T., Meisinger, C., Thorand, B., Ruepp, A., Hrabé de Angelis, M., Li, Y., Wichmann, H.-E., Stratmann, B., Strauch, K., Metspalu, A., Gieger, C., Suhre, K., Adamski, J., Illig, T., Rathmann, W., Roden, M., Peters, A., van Duijn, C. M., Boomsma, D. I., Meitinger, T., & Wang-Sattler, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-06-08
- Volume
- 38
- Issue
- 10
- Pages
- 1858-1867
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1824516519
- Cited by
- 139
- References
- 13
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc15-0658
- The paper
- Xu, T., Brandmaier, S., Messias, A. C., Herder, C., Draisma, H. H. M., Demirkan, A., Yu, Z., Ried, J. S., Haller, T., Heier, M., Campillos, M., Fobo, G., Stark, R., Holzapfel, C., Adam, J., Chi, S., Rotter, M., Panni, T., Quante, A. S., . . . Wang-Sattler, R. (2015). Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc15-0658
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.